{"commentary":{"count":30,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":13,"podcast":11,"youtube":6},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05186974\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"EVOKE-02","nct_id":"NCT05186974","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=evoke-02-nct05186974. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"EVOKE-02","arms":[{"description":"Participants assigned to Cohorts A according to tumor proportion score (TPS) status will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle.","label":"Sacituzumab Govitecan-hziy (SG) + Pembrolizumab (Cohort A)","type":"EXPERIMENTAL"},{"description":"Participants assigned to Cohorts B according to TPS status will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle.","label":"SG + Pembrolizumab (Cohort B)","type":"EXPERIMENTAL"},{"description":"Participants will receive SG (de-escalating dose levels: 10.0 mg/kg, 7.5 mg/kg, or 5.0 mg/kg) on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + carboplatin area under the concentration versus time curve (AUC)5 on Day 1 of a 21-day cycle.","label":"SG + Pembrolizumab + Carboplatin Safety Run-in","type":"EXPERIMENTAL"},{"description":"Participants will receive SG (either 10 mg/kg or 7.5 mg/kg) on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + cisplatin 75 mg/m\\^2 on Day 1 of a 21-day cycle.","label":"SG + Pembrolizumab + Cisplatin Safety Run-in (Optional)","type":"EXPERIMENTAL"},{"description":"Participants assigned to Cohort C according to disease status will receive SG RP2D as determined during the safety run-in cohorts on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + carboplatin AUC5 or cisplatin 75 mg/m\\^2 as determined during the safety run-in cohorts on Day 1 of a 21-day cycle.","label":"SG + Pembrolizumab + Carboplatin or Cisplatin (Cohort C)","type":"EXPERIMENTAL"},{"description":"Participants assigned to Cohort D according to disease status will receive SG RP2D as determined during the safety run-in cohorts on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + carboplatin AUC5 or cisplatin 75 mg/m\\^2 as determined during the safety run-in cohorts on Day 1 of a 21-day cycle.","label":"SG + Pembrolizumab + Carboplatin or Cisplatin (Cohort D)","type":"EXPERIMENTAL"},{"description":"Participants assigned to Cohort E will receive SG RP2D, as determined following safety review of Cohorts C and D, on Days 1 and 8 of a 21-day cycle + pembrolizumab 200 mg on Day 1 of a 21-day cycle + cisplatin 75 mg/ m\\^2 on Day 1 of a 21-day cycle.","label":"SG + Pembrolizumab + Cisplatin (Cohort E)","type":"EXPERIMENTAL"}],"collaborators":["Merck Sharp & Dohme LLC"],"completion_date":{"date":"2027-03","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":193,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Sacituzumab Govitecan-hziy (SG)","type":"DRUG"},{"name":"Pembrolizumab","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"}],"last_update":"2026-09-11","lead_sponsor":"Gilead Sciences","official_title":"An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-03","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective Response Rate as Assessed by Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1","timeFrame":"Up to 22 Months"},{"measure":"Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) per Dose Level in the Safety Run-in Cohorts","timeFrame":"First dose date up to 21 days"}],"references":[{"citation":"Reck M, Patel JD, Gray JE, Reguart N, Cobo M, Pradera JF, Felip E, Cappuzzo F, Garon EB, Neal JW, Mekan S, Safavi F, Fernando N, Zavodovskaya M, Jurgensmeier JM, Chisamore M, Cho BC. First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study. J Thorac Oncol. 2026 Mar;21(3):103509. doi: 10.1016/j.jtho.2025.10.016. Epub 2025 Oct 30.","pmid":"41173143","type":"DERIVED"}],"start_date":{"date":"2022-05-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)","url":"https://clinicaltrials.gov/study/NCT05186974"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/evoke-02-nct05186974"}